USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus'' USA Office with nil observations.

September 26, 2026 BSE Limited Code: 532321 P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Press Release Dear Sir / Madam, Please find enclosed a copy of press release dated September 26, 2026, titled “USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus’ USA Office with nil observations”. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large. Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus’ USA Office with nil observations Ahmedabad, India, 26 September 2026 We wish to inform that the USFDA conducted onsite inspection of pharmacovigilance and post marketing surveillance system at the company’s office based in New Jersey, USA. The inspection was conducted from 22nd September to 25th September 2026. The inspection closed with NIL observations. This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.